REG - Ergomed plc - Result of AGM

ErgomedAnnouncement

10/06/2020 10:55

RNS Number : 5431P
  
Ergomed plc
  
10 June 2020
  
 

 
 
PRESS RELEASE
 
Results of 2020 Annual General Meeting 
 
Guildford, UK - 10 June 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting ('AGM') held earlier today.  All resolutions were duly passed.
 
Details of the voting by way of a poll at the AGM in respect of each resolution are shown in the table below:
 



Resolution number


Votes for


Votes against


Abstentions




1


40,377,405


755,572


26,824




2


41,074,246


84,305


1,250




3


41,121,902


37,899


Nil




4


41,148,702


9,849


1,250




5


34,189,991


6,044,148


925,662




6


40,732,147


426,404


1,250




7


36,281,712


4,878,089


Nil




8


33,049,246


8,109,305


1,250




9


33,049,891


8,109,910


Nil



 
The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com
 
ENDS
 
Enquiries:
 



Ergomed plc


 Tel: +44 (0) 1483 402 975




Miroslav Reljanović (Executive Chairman)








Richard Barfield (Chief Financial Officer)
 


















 
Numis Securities Limited


 
Tel: +44 (0) 20 7260 1000




Freddie Barnfield / Huw Jeremy (Nominated Adviser)








James Black (Broker)
 


















 
Consilium Strategic Communications - for UK enquiries


 
Tel: +44 (0) 20 3709 5700




Chris Gardner / Sue Stuart


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser

















 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
RAGFIFEARFIILII